Funding

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Jack discusses her greatest accomplishments, advice for industry leaders, and the promise of biotech. Pulmatrix is a clinical trial stage biotech company based in Lexington, Mass.

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

What is your opinion of biotechnology companies – very favorable, somewhat favorable, somewhat unfavorable, or very unfavorable?

Mankind's need to cure disease, combat hunger and discover new forms of energy has never been more urgent.

BIOtechNOW’s Tracy Cooley talks to Dr. Schubert of the  Bioscience Association of West Virginia about biotech in West Virginia – major areas of growth, the outlook for growth of the industry within the states, and plans for the upcoming  BIO International Convention.

Biofuels Digest and BIO have launched the Summer 2011 Bioenergy Business Outlook Survey.

BIO and five member companies – Mendel Biotechnology, Arborgen, Abengoa Bioenergy, Novozymes and BP Biofuels – along with the Biomass Power Association held a briefing on Capitol Hill this week, outlining the importance of the USDA’s Biomass Crop Assistance Program (BCAP) and related programs. Regulatory rules for the BCAP, Biorefinery Assistance Program, and Rural Energy for America Program (REAP) were finalized by USDA only during the last quarter of 2010. But Congress is considering cutting the funds for these programs before they have a chance to show their effectiveness.

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International Convention is an intensive three day course designed for entrepreneurial scientists.

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International convention is an intensive three day course designed for entrepreneurial scientists, CEOs, CSOs and business development professionals of early stage companies in the life sciences who are aspiring entrepreneurs.

The Biotechnology Entrepreneurship Boot Camp at the 2011 BIO International convention is an intensive three day course designed for entrepreneurial scientists, CEOs, CSOs and business development professionals of early stage companies in the life sciences who are aspiring entrepreneurs.

Fine, University of Maryland Dingman Center for Entrepreneurship and local co-chair of the Boot Camp, discusses the event, who should attend and what they can expect to learn.

July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.  
May 17 2011
BIO encourages Congress to support advanced biofuels and biobased products programs and initiatives during consideration of the Fiscal Year 2012 Energy & Water Appropriations bill. Industrial biotechnology is the key enabling technology that is causing a dramatic paradigm shift in the production of fuels and chemicals. By building modern biorefineries and using industrial biotechnology our nation could significantly reduce its dependence on foreign sources of oil.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.
July 10 2013
Chimerix President and CEO emphasizes the role of the public market to help finance critical R&D.
June 14 2012
Support Of Industry Underscores Pro-Business Commitment
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."